The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported ...

Please provide your email address to receive an email when new articles are posted on . Meta-analysis further supports catheter ablation vs. drug therapy for management of ventricular arrythmias ...

The drug at the heart of its deal with Novartis, called farabursen, entered the clinic in 2022. Farabursen targets miR-17, which researchers have identified as potentially relevant to kidney disease.

Diseases that involve pathological hyperactivity of NMDARs can be treated clinically through inhibition by channel blocking drugs. NMDAR channel block can occur via two known mechanisms. First, in ...

For many years, the only treatment for ventricular arrhythmias was antiarrhythmic drugs, but catheter ablation has since been used to reduce overall arrhythmia burden, VT storm, ICD shocks, and ...

There were no unexpected health problems linked to using the two drugs together, giving doctors and patients more confidence in this treatment option. The research, led by Dr. Serge Jabbour and ...

These steroids are anti-inflammatory drugs, the cornerstone of asthma therapy. There are many benefits of using anti-inflammatory asthma inhalers to manage asthma. To learn more about using ...

“We should be doing all that we can to protect this first-line treatment and to ensure that the worst-case scenario of increased drug resistance projected by this UCL modelling exercise does not ...

03). Adverse events within 30 days post-procedure included death in 1% of patients and nonfatal adverse events in 11.3% of patients, while adverse events in the antiarrhythmic drug treatment group ...

Six antiarrhythmic drugs are often used to treat atrial fibrillation: propafenone, flecainide, Betapace (sotalol), Tikosyn (dofetilide), amiodarone, and Multaq (dronedarone). For anybody taking these ...

A novel combination therapy offers better outcomes for patients ... In January, the Food and Drug Administration (FDA) approved the combination to treat patients with metastatic KRAS G12C mutated ...

AB Science SA (Euronext - FR0010557264 - AB) announces today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted orphan drug status to AB8939 for the ...